Linux kernel newbies em português

Glioblastoma is a common malignant primary brain tumor, despite standard therapy in continuous improvement, but the median survival of patients is still only about 15 months, if left untreated patients with a median survival of only 4 months; recently, scientists from Thomas Jefferson University have developed a new cancer vaccine, which can withstand the brain tumor patients by activating the body's immune system to prolong the patient's life, research published in the international Journal of cancer Immunology, on Immunotherapy, the research or for the treatment of malignant glioma development of new experimental therapies offer hope and help.

Dr. Craig Hooper said that in recent years, researchers have come to realize the role of the immune system in cancer prevention and treatment of individuals in the development process, the immune system can potentially help fight cancer effectively, but this study is based on the development of the brain cancer vaccine. This paper reports the results of the second phase of clinical studies, the first phase of the study began in 2001, at the beginning of the study, researchers found that 12 patients were tested eight patients with tumor shrinkage of the body, the vaccine contains a section patients with tumors of the body, especially the use of special drugs overnight treatment since the tumor tissue removed during surgery, which was subsequently implanted in the patient abdomen wrapped in the "diffusion box", in particular the use of drug therapy called antisense oligonucleotides (Human Haptoglobin ELISA Kit http://www.cusabio.com/ELISA_Kit-83112/ ), which can drive the spread of cancer knockout IGF-R1 receptor molecules and growth, and the use of AS-ODN-like formulations blocking IGF-R1 receptors can promote cancer cell self-destruction.

Initial experiments, researchers believe that the self-destruction of tumor tissue from the patient in the molecule can be released by diffusion chamber, thereby activating the immune system, once it has been activated in the abdominal tissue, immune cells into the brain will kill residual tumor cells . The researchers said that used to kill cancer cells AS-ODN drug molecules can also activate the immune system, and AS-ODN therapy can alter tumor cells to release the outer core body.

Researchers currently in 12 recurrent glioblastoma patients recruited in the latest detection of the new cancer vaccine efficacy, this round of testing, there are six patients had an immune response to the therapy, without generating an immune response perhaps there are some patients with immunodeficiency. The next step will be a clinical trial conducted in January 2015, the researchers plan to brain tumor patients were first tested after removal surgery, the researchers hope the majority of these patients may benefit from new cancer vaccine testing. Researchers are now looking for another way to enhance the immune response to cancer vaccine to make it more effective.